Tuberculous peritonitis
ICD-10 A18.31 is a billable code used to indicate a diagnosis of tuberculous peritonitis.
Tuberculous peritonitis is a rare form of extrapulmonary tuberculosis that occurs when Mycobacterium tuberculosis infects the peritoneal cavity. This condition can arise from hematogenous spread from a primary pulmonary infection or from direct extension from adjacent organs. Patients may present with abdominal pain, ascites, fever, and weight loss. Diagnostic methods include imaging studies such as ultrasound or CT scans to identify fluid accumulation, and paracentesis may be performed to analyze peritoneal fluid for the presence of acid-fast bacilli or elevated adenosine deaminase levels. Treatment typically involves a combination of antituberculous medications, including isoniazid, rifampicin, ethambutol, and pyrazinamide, for a duration of at least six months. Monitoring for drug resistance is crucial, as multidrug-resistant tuberculosis (MDR-TB) can complicate treatment. Public health implications are significant, as tuberculous peritonitis can indicate disseminated tuberculosis, necessitating contact tracing and isolation procedures for infectious patients. Early diagnosis and appropriate management are essential to prevent complications and improve patient outcomes.
Detailed history of exposure, diagnostic tests performed, treatment plan, and follow-up care.
Patients presenting with abdominal symptoms and a history of tuberculosis or exposure to TB.
Documentation must include rationale for diagnostic tests and any drug resistance testing performed.
Comprehensive assessment of abdominal symptoms, imaging results, and fluid analysis.
Patients with ascites and suspected infectious causes.
Ensure clarity in distinguishing between tuberculous and non-tuberculous peritonitis.
Used when fluid analysis is needed to confirm diagnosis.
Document indication for procedure, fluid analysis results, and any complications.
Infectious disease specialists should ensure proper coding for diagnostic procedures.
Common symptoms include abdominal pain, ascites, fever, and weight loss. Patients may also experience gastrointestinal symptoms such as nausea and vomiting.
Diagnosis is typically made through imaging studies, paracentesis for fluid analysis, and microbiological testing for Mycobacterium tuberculosis.
Treatment involves a combination of antituberculous medications, typically including isoniazid, rifampicin, ethambutol, and pyrazinamide, for at least six months.
